Zogenix Says Zohydro ER Demonstrates Sustained 12-Hour Pain Relief

(RTTNews) - Zogenix, Inc. (ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system disorders, Tuesday announced new post-hoc analysis data showing that the indicated 12-hour dose of Zohydro ER, (hydrocodone bitartrate) Extended-Release Capsules, CII, provided durable pain relief over the entire dosing interval.

This finding is important as a major concern for all extended-release pain medications is the potential for lack of consistent pain relief throughout the entire day, especially at the end of dosing.

"In this study, we saw that most of the chronic pain patients taking Zohydro ER achieved effective pain relief for the entire duration of 12 hours for each administered dose. In particular, most patients did not experience dose failures during the night, meaning they did not wake up to take additional medication for their pain," said Srinivas Nalamachu, President and Medical Director, International Clinical Research Institute, Overland Park, Kansas.

The goal of extended-release opioids is to provide sustained delivery of medication and continuous pain relief over the entire dosing interval, reducing or eliminating the need to take rescue pain medication.

Chronic pain patients experiencing interruptions in sleep frequently have higher degrees of pain and reduced functioning the following day.

These data will be presented at PAINWeek, the national conference on pain for clinicians specializing in pain management taking place this week in Las Vegas.